PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 31/35	A1	(11) International Publication Number: WO 00/15219
		(43) International Publication Date: 23 March 2000 (23.03.00)

(21) International Application Number: PCT/SE99/01598

(22) International Filing Date: 13 September 1999 (13.09.99)

(30) Priority Data:
9803157–8 16 September 1998 (16.09.98) SE

(71) Applicant *(for all designated States except US)*: ASTRA AKTIEBOLAG [SE/SE]; S–151 85 Södertälje (SE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: EVENDEN, John [GB/US]; Astra Arcus USA, Inc., P.O. Box 20890, Rochester, NY 14603 (US). THORBERG, Seth–Olov [SE/SE]; Astra Arcus AB, S–151 85 Södertälje (SE).

(74) Agent: ASTRA AKTIEBOLAG; Intellectual Property, Patents, S–151 85 Södertälje (SE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With amended claims.

(54) Title: A NEW COMPOSITION

(57) Abstract

The invention relates to a composition comprising a first component (a) which is *(R)*–3–*N,N*–dicyclobutylamino–8–fluoro–3,4–dihydro–2*H*–1–benzopyran–5–carboxamide hydrogen (2*R*,3*R*)–tartrate monohydrate and a second component (b) which is 1–[3–(dimethylamino)propyl]–1–(p–fluorophenyl)–5–phthalancarbonitrile, as the racemate or an enantiomer thereof, in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof, the preparation thereof, pharmaceutical formulations containing said composition, use of and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition as well as a kit containing said composition.